2. Search Result
Search Result
Results for "

SLC7A11

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

4

Natural
Products

1

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149979
    SLC7A11-IN-1

    		Apoptosis Cancer
    SLC7A11-IN-1 is a potent solute carrier family 7 member 11 (SLC7A11, xCT) inhibitor. SLC7A11-IN-1 shows antiproliferative activity. SLC7A11-IN-1 inhibits cell invasion and metastasis. SLC7A11-IN-1 induces Apoptosis and cell cycle arrest at S-phase. SLC7A11-IN-1 shows anti-tumor activity .
    SLC7A11-IN-1
  • HY-W451275
    HG106

    		Apoptosis Cancer
    HG106 is an effective SLC7A11 inhibitor. HG106 mediates apoptosis by increasing oxidative stress and endoplasmic reticulum stress, and it has antitumor activity .
    HG106
  • HY-W402682
    SXC2023

    		Others Neurological Disease Cancer
    SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and ameliorates central nervous system disorder through downregulation of glutamate export .
    SXC2023
  • HY-B0653A
    Levobupivacaine hydrochloride
    2 Publications Verification

    (S)-(-)-Bupivacaine monohydrochloride

    		 Sodium Channel Ferroptosis Cardiovascular Disease Neurological Disease Cancer
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
    Levobupivacaine hydrochloride
  • HY-RS13325
    SLC7A11 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SLC7A11 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC7A11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SLC7A11 Human Pre-designed siRNA Set A
    SLC7A11 Human Pre-designed siRNA Set A
  • HY-162942
    SLC7A11-IN-3

    		Others Cancer
    SLC7A11-IN-3 (Compound 42711_11) is an inhibitor of SLC7A11 .
    SLC7A11-IN-3
  • HY-169056
    SLC7A11-IN-2

    		Others Cancer
    SLC7A11-IN-2 (Compound 1) is an SLC7A11/xCT inhibitor. SLC7A11-IN-2 induces cell death in HeLa cells by lowering intracellular glutathione levels and increasing oxidative stress, thereby disrupting the oxidative balance within the cells, with an IC50 value of 10.23 μM. Molecular dynamics simulation analysis indicates that SLC7A11-IN-2 has a stronger binding affinity to SLC7A11 compared to Erastin (HY-15763). SLC7A11-IN-2 can be utilized in research within the field of cervical cancer .
    SLC7A11-IN-2
  • HY-155852
    Lepadin H

    		Ferroptosis Others
    Lepadin H is a marine alkaloid and ferroptosis inducer. Lepadin H exhibits significant cytotoxicity, promotes p53 expression, increases ROS production and lipid peroxidation, decreases SLC7A11 and GPX4 levels, and upregulates ACSL4 expression. Lepadin H induces ferroptosis through the p53-SLC7A11-GPX4 pathway .
    Lepadin H
  • HY-155851
    Lepadin E

    		Ferroptosis MDM-2/p53 Glutathione Peroxidase Cancer
    Lepadin E is a significantly cytotoxic ferroptosis inducer that induces iron death through the classical p53-SLC7A11-GPX4 pathway. Lepadin E promoted p53 expression, decreases SLC7A11 and GPX4 levels, and leads to increased ROS and lipid peroxide production, and upregulated ACSL4 expression, thus causes cell death. Lepadin E has significant antitumor effect .
    Lepadin E
  • HY-B0653
    Levobupivacaine

    (S)-(-)-Bupivacaine

    		 Sodium Channel Ferroptosis Neurological Disease Cancer
    Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
    Levobupivacaine
  • HY-15763
    Erastin
    Maximum Cited Publications
    408 Publications Verification

    		 VDAC Ferroptosis Disulfidptosis Cancer
    Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
    Erastin
  • HY-161075
    Microtubule inhibitor 8

    		Microtubule/Tubulin Ferroptosis Cancer
    Microtubule inhibitor 8 (MP-HJ-1b) is a potent inhibitor of microtubule. Microtubule inhibitor 8 triggers cell death through ferroptosis. Microtubule inhibitor 8 has anti-tumor effect .
    Microtubule inhibitor 8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: